RecruitingPhase 2NCT04924075
Endocrine
Pheochromocytoma and Paraganglioma
Also known as PPGL, pheo, pheochromocytoma, SDH-related paraganglioma
Pheochromocytoma and Paraganglioma are rare catecholamine-secreting tumours arising from chromaffin cells of the adrenal medulla (pheochromocytoma) or extra-adrenal sympathetic and parasympathetic ganglia (paraganglioma). Approximately 40%
35
studies recruiting now
as of 7 Sept 2026
165
studies registered in total
as of 7 Sept 2026
25
countries with a recruiting site
as of 7 Sept 2026
11 Jun 2021
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT01660984
Natural History Study of Children and Adults With Medullary Thyroid Cancer
RecruitingNCT02402244
Project: Every Child for Younger Patients With Cancer
RecruitingPhase 2NCT03206060
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RecruitingNCT00001238
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 35 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Pheochromocytoma and Paraganglioma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: ENSAT Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Pheochromocytoma and Paraganglioma
Pheochromocytoma and Paraganglioma are rare catecholamine-secreting tumours arising from chromaffin cells of the adrenal medulla (pheochromocytoma) or extra-adrenal sympathetic and parasympathetic ganglia (paraganglioma). Approximately 40% of cases are caused by germline mutations in one of over 20 susceptibility genes, with SDH subunit mutations (particularly SDHB) associated with a markedly elevated risk of malignant disease and metastasis. Diagnosis relies on measurement of fractionated metanephrines in plasma or urine combined with functional imaging using 68Ga-DOTATATE or 123I-MIBG scintigraphy.
Common clinical features
Hypertension, often paroxysmal or refractoryHeadache, palpitations, and diaphoresis (classic triad)Pallor during hypertensive crisesAnxiety and panic-like episodesHyperglycaemiaWeight lossIncidentally discovered adrenal or para-aortic massMetastatic disease (lymph nodes, bone, liver, lung) in malignant PPGL
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Pheochromocytoma and Paraganglioma. Not eligibility rules; those are set by each study.
- Germline genetic testing is recommended for all PPGL patients regardless of family history; the specific mutation (especially SDHB for malignant risk) affects eligibility for targeted systemic therapy trials.
- Biochemical evidence of active catecholamine secretion (elevated plasma metanephrines) is required for most trials; ensure results are collected under standardised conditions (fasting, supine, off interfering medications).
- For malignant PPGL trials, prior treatment lines (surgery, MIBG therapy, chemotherapy) and measurable disease by RECIST criteria on cross-sectional imaging are standard eligibility requirements.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).